PE20140872A1 - Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple - Google Patents

Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple

Info

Publication number
PE20140872A1
PE20140872A1 PE2013001357A PE2013001357A PE20140872A1 PE 20140872 A1 PE20140872 A1 PE 20140872A1 PE 2013001357 A PE2013001357 A PE 2013001357A PE 2013001357 A PE2013001357 A PE 2013001357A PE 20140872 A1 PE20140872 A1 PE 20140872A1
Authority
PE
Peru
Prior art keywords
laquinimod
improve
patients
life
multiple sclerosis
Prior art date
Application number
PE2013001357A
Other languages
English (en)
Spanish (es)
Inventor
Nora Tarcic
Dan Bar-Zohar
Dina Kofler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140872(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PE20140872A1 publication Critical patent/PE20140872A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2013001357A 2010-12-07 2011-12-06 Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple PE20140872A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42074210P 2010-12-07 2010-12-07
US201161542996P 2011-10-04 2011-10-04

Publications (1)

Publication Number Publication Date
PE20140872A1 true PE20140872A1 (es) 2014-08-09

Family

ID=46162796

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001357A PE20140872A1 (es) 2010-12-07 2011-12-06 Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple

Country Status (19)

Country Link
US (1) US20120142730A1 (enExample)
EP (1) EP2648732A4 (enExample)
JP (2) JP2013544887A (enExample)
KR (1) KR20130124518A (enExample)
CN (1) CN103260624B (enExample)
AU (2) AU2011338647A1 (enExample)
BR (1) BR112013014061A2 (enExample)
CA (1) CA2820586A1 (enExample)
CL (1) CL2013001602A1 (enExample)
EA (1) EA201390827A1 (enExample)
IL (1) IL250726A0 (enExample)
MX (1) MX2013006464A (enExample)
NZ (1) NZ611628A (enExample)
PE (1) PE20140872A1 (enExample)
PH (1) PH12013501193A1 (enExample)
SG (2) SG190449A1 (enExample)
UA (1) UA111959C2 (enExample)
WO (1) WO2012078591A1 (enExample)
ZA (1) ZA201304237B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201508623RA (en) * 2005-10-19 2015-11-27 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
ES2564931T3 (es) * 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
CA2771203C (en) 2009-08-10 2019-04-09 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
WO2011109526A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
MX2012010066A (es) * 2010-03-03 2012-10-03 Teva Pharma Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato.
CN104610144A (zh) 2010-07-09 2015-05-13 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
WO2014052933A1 (en) * 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
WO2014127139A1 (en) * 2013-02-15 2014-08-21 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
EP2970129A2 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
MX2015010967A (es) 2013-03-14 2015-10-26 Teva Pharma Formulaciones transdermicas de laquinimod.
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod
KR20170005434A (ko) * 2014-04-29 2017-01-13 테바 파마슈티컬 인더스트리즈 리미티드 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드
WO2016059571A1 (en) * 2014-10-16 2016-04-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
CA3115269A1 (en) * 2018-10-09 2020-04-16 Medicinova, Inc. Combination of ibudilast and interferon-beta and methods of using same
EP4003338A1 (en) * 2019-07-22 2022-06-01 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
CN110688373A (zh) * 2019-09-17 2020-01-14 杭州绿度信息技术有限公司 一种基于逻辑回归的offset方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1797109T3 (en) * 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20150065951A (ko) * 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
DK2653873T3 (da) * 2007-02-08 2022-07-25 Biogen Ma Inc Sammensætninger og anvendelser til behandling af multipel sklerose
EP2442651B1 (en) * 2009-06-19 2015-07-29 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod

Also Published As

Publication number Publication date
ZA201304237B (en) 2014-08-27
MX2013006464A (es) 2013-07-29
PH12013501193A1 (en) 2013-07-15
EP2648732A4 (en) 2014-04-30
AU2011338647A8 (en) 2013-09-05
US20120142730A1 (en) 2012-06-07
IL250726A0 (en) 2017-04-30
BR112013014061A2 (pt) 2016-09-13
NZ611628A (en) 2015-06-26
CA2820586A1 (en) 2012-06-14
AU2011338647A1 (en) 2013-07-04
UA111959C2 (uk) 2016-07-11
EP2648732A1 (en) 2013-10-16
SG10201509831XA (en) 2015-12-30
CL2013001602A1 (es) 2013-10-25
CN103260624A (zh) 2013-08-21
KR20130124518A (ko) 2013-11-14
JP2017095476A (ja) 2017-06-01
SG190449A1 (en) 2013-07-31
CN103260624B (zh) 2015-06-03
AU2017202055A1 (en) 2017-04-20
WO2012078591A8 (en) 2012-08-02
JP2013544887A (ja) 2013-12-19
EA201390827A1 (ru) 2013-12-30
WO2012078591A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
EA201390827A1 (ru) Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
RU2014109074A (ru) ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
NZ589445A (en) Rasagiline for parkinson's disease modification
MX362626B (es) Métodos para tratar pacientes pediátricos usando dexmedetomidina..
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
PH12014500386A1 (en) Combination treatment for hepatitis c
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
FI3439660T3 (fi) Pimobendaanin käyttö sydämen koon pienentämiseen ja kliinisten oireiden alkamisen hidastamiseen potilaissa, joilla on hiippaläppäsairaudesta johtuva oireeton sydämen vajaatoiminta
MX344303B (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
MX361741B (es) Tratamientos médicos a base de anamorelina.
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX2015014939A (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
NZ597675A (en) Medicament for the long term nsaid use
MX2021016090A (es) Lemborexant para el tratamiento de problemas del sueño.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2015005486A (es) Usos de bremelanotida en terapia para la disfuncion sexual femenina.
AR080380A1 (es) Tratamiento de la demencia tipo alzheimer con masitinib
NZ599227A (en) Therapeutic agent for chronic pain
RU2008107113A (ru) Средство и способ профилактики и лечения пациентов с болезнью альцгеймера

Legal Events

Date Code Title Description
FC Refusal